PRINCETON, N.J., May 13, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing cancer immunotherapies, announced that principal investigator Nicola Mason, BVet.Med, PhD, DACVIM, of the University of Pennsylvania School of Veterinary Medicine, will present updated data from the ongoing ADXS-cHER2 study in canine osteosarcoma at the 2014 American College of Veterinary Internal Medicine (ACVIM) Forum on Thursday, June 5th at 4:25-5:15 p.m.in Nashville, TN. ADXS-cHER2 is an immunotherapy that targets the HER2 oncogene, which is overexpressed in certain solid-tumor cancers, including pediatric bone cancer and breast cancer. In her presentation, "Clinical Evaluation of a HER2/neu-Targeting Vaccine to Prevent Metastatic Osteosarcoma", Dr. Mason will provide updated data from the ongoing study in pet dogs with osteosarcoma.
"We are excited that Dr. Mason will be presenting these encouraging data from our canine trial at the ACVIM Forum, which focuses on the latest developments in animal-health," said Daniel J. O'Connor, Chief Executive Officer of Advaxis. "Without question, her research has not only been groundbreaking in the treatment of canine osteosarcoma, but the results have also affirmed the potential of ADXS-cHER2 as a treatment for a host of human cancers, including bone cancer and breast cancer, where the HER2 oncogene is overexpressed. In particular, these data, along with the strong parallel between canine and pediatric bone cancer, were instrumental in our recent decision to pursue a clinical development program with ADXS-cHER2 in pediatric osteosarcoma."
About Advaxis, Inc.
Advaxis is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. The Advaxis technology, using bioengineered live attenuated bacteria, is the only cancer immunotherapy shown to actively suppress Tregs and MSDCs, key components in the cancer microenvironment that contribute to tumor growth and protect it from immunologic attack. Advaxis's lead immunotherapy, ADXS-HPV, targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase 2 in invasive cervical cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The FDA has granted Advaxis orphan drug status for each of these three indications. The Company plans to initiate a registrational clinical program for cervical cancer in 2014 and has established licensing partners in India and Asia for commercialization in those regions. Advaxis's second immunotherapy candidate, ADXS-cHER2, targets the HER2 oncogene, which is overexpressed in certain solid-tumor cancers, including pediatric bone cancer (or osteosarcoma), breast cancer, and gastric cancer. Advaxis is developing ADXS-cHER2 for both human and animal-health, and has seen promising results in canine osteosarcoma, a model for human bone cancer. Advaxis is pursuing a clinical program in pediatric osteosarcoma and has licensed ADXS-cHER2 and three other immunotherapy constructs to a major animal-health company.
Advaxis has created more than 15 distinct immunotherapies based on its platform, either directly or through strategic collaborations with recognized cancer centers of excellence such as: the University of Pennsylvania, Brown University, the Georgia Regents University Cancer Center, the Icahn School of Medicine at Mount Sinai, and others.
For more information please visit www.advaxis.com or connect with us on
- Facebook: https://www.facebook.com/advaxisinc
- Twitter: https://twitter.com/Advaxis
- LinkedIn: http://www.linkedin.com/company/advaxis-inc.
- Google+: https://plus.google.com/b/115126287957745987074/115126287957745987074/posts
This news release contains forward-looking statements, including, but not limited to: statements regarding Advaxis' ability to develop the next generation of cancer immunotherapies; the safety and efficacy of Advaxis' proprietary immunotherapy, ADXS-HPV; whether Advaxis immunotherapies can redirect the powerful immune response all human beings have to the bacterium to cancers. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Advaxis' SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2013, which is available at http://www.sec.gov. Advaxis undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.
CONTACT: Advaxis Contact: Lisa Caperelli Senior Director of Investor Relations and Corporate Communications Advaxis, Inc. email@example.com 215.206.1822 Media Contact: Tiberend Strategic Advisors, Inc. Amy S. Wheeler firstname.lastname@example.org 646.362.5750